Page contentsKey factsDecisionRelated contentTopicsKey factsInvented nameVargatef; OfevVargatefOfevActive SubstancenintedanibTherapeutic areaOncologyDecision numberP/0124/2017PIP numberEMEA-001006-PIP03-16Pharmaceutical form(s)Capsule (soft)Condition(s) / indication(s)Treatment of lung carcinoma (small cell and non-small cell carcinoma)Treatment of mesotheliomaRoute(s) of administrationOral useContact for public enquiriesBoehringer Ingelheim International GmbHTel. +49 6132 778271Email: Paediatrics@boehringer-ingelheim.comDecision typeW: decision granting a waiver in all age groups for all conditions or indicationsDecision date05/05/2017DecisionP/0124/2017: EMA decision of 5 May 2017 on the granting of a product-specific waiver for nintedanib (Vargatef, Ofev), (EMEA-001006-PIP03-16)AdoptedReference Number: EMA/260237/2017 English (EN) (71.03 KB - PDF)First published: 03/07/2017Last updated: 03/07/2017ViewRelated contentVargatefOfevTopicsPaediatricsShare this pageHow useful do you find this page?12345